Clinical genitourinary cancer · 2026
Clinical Outcomes of Neuroendocrine Prostate Cancer Treated With Platinum-Based Chemotherapy: A Single-Institution Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wee Christopher E, Nizam Amanda, Ornstein Moshe C, Chen Yanwen, Rao Santosh, Dedousis Demetrios, Gilligan Timothy D, Moningi Shalini, Campbell Rebecca, Gupta Shilpa
Аннотация
INTRODUCTION: Neuroendocrine prostate cancer (NEPC) is aggressive with a poor prognosis. Most reported series derive from large databases (e.g., SEER) lacking granular clinical detail. We examined our institution's experience with 58 patients with NEPC.
PATIENTS: We identified patients with biopsy-proven NEPC treated with platinum-based chemotherapy. De novo versus treatment-emergent (t-NEPC) status, stage, and treatment history were recorded.
METHODS: For localized NEPC treated with definitive intent, disease-free survival (DFS) was measured from NEPC diagnosis to relapse or death; for metastatic NEPC, systemic therapies were noted. Overall survival (OS) was defined as time from NEPC diagnosis to death and estimated by Kaplan-Meier method, with log-rank comparisons.
RESULTS: Fifty-eight patients with NEPC were identified (median age, 66 years); 19 (32.8%) had de novo NEPC and the remainder had t-NEPC. Forty-four (75.9%) had metastatic disease at NEPC diagnosis. Histology was pure small cell (n = 15), neuroendocrine (n = 21), or mixed (n = 22, e.g., with adenocarcinoma). Of 14 patients without metastases at diagnosis, 10 received definitive local therapy (median DFS, 11.7 months). OS was longer for de novo versus t-NEPC disease (26.5 vs 10.9 months, P = 0.0001) and for mixed versus pure histology (21.0 vs 11.0 months, P = 0.0002). Among 45 patients with metastatic NEPC treated with first-line carboplatin and etoposide, OS did not differ with versus without maintenance immunotherapy (12.5 vs 11.0 months, P = 0.9).
CONCLUSION: In one of the largest non-database series of patients with NEPC, OS was longer for de novo disease and mixed histology. Maintenance IO after carboplatin plus etoposide was not associated with improved OS.
PATIENTS: We identified patients with biopsy-proven NEPC treated with platinum-based chemotherapy. De novo versus treatment-emergent (t-NEPC) status, stage, and treatment history were recorded.
METHODS: For localized NEPC treated with definitive intent, disease-free survival (DFS) was measured from NEPC diagnosis to relapse or death; for metastatic NEPC, systemic therapies were noted. Overall survival (OS) was defined as time from NEPC diagnosis to death and estimated by Kaplan-Meier method, with log-rank comparisons.
RESULTS: Fifty-eight patients with NEPC were identified (median age, 66 years); 19 (32.8%) had de novo NEPC and the remainder had t-NEPC. Forty-four (75.9%) had metastatic disease at NEPC diagnosis. Histology was pure small cell (n = 15), neuroendocrine (n = 21), or mixed (n = 22, e.g., with adenocarcinoma). Of 14 patients without metastases at diagnosis, 10 received definitive local therapy (median DFS, 11.7 months). OS was longer for de novo versus t-NEPC disease (26.5 vs 10.9 months, P = 0.0001) and for mixed versus pure histology (21.0 vs 11.0 months, P = 0.0002). Among 45 patients with metastatic NEPC treated with first-line carboplatin and etoposide, OS did not differ with versus without maintenance immunotherapy (12.5 vs 11.0 months, P = 0.9).
CONCLUSION: In one of the largest non-database series of patients with NEPC, OS was longer for de novo disease and mixed histology. Maintenance IO after carboplatin plus etoposide was not associated with improved OS.